<DOC>
	<DOCNO>NCT01876966</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetic interaction etravirine artemether/lumefantrine darunavir/ritonavir artemether/lumefantrine healthy Human Immunodeficiency Virus- ( HIV- ) negative patient . 'Pharmacokinetic interaction ' mean one medication influence absorption elimination body medication .</brief_summary>
	<brief_title>Interaction Between Etravirine Darunavir/Ritonavir Artemether / Lumefantrine</brief_title>
	<detailed_description>This Phase I , partially randomize , open-label , single-center , two-way , two-period cross-over study investigate pharmacokinetic interaction etravirine ( ETR ) darunavir/ritonavir ( DRV/rtv ) antimalarial drug artemether/lumefantrine steady-state healthy human immunodeficiency virus ( HIV ) -negative patient . The study population consist 32 healthy patient , equally divide 2 panel . Patients Panel 1 treated ETR artemether/lumefantrine ; patient Panel 2 treated DRV/rtv artemether/lumefantrine . Treatment A consist 3 day treatment artemether/lumefantrine . Treatment B consist 200 mg ETR twice daily ( b.i.d . ) ( Panel 1 ) 600/100 mg DRV/rtv b.i.d . ( Panel 2 ) Day 1 Day 21 single dose ETR ( Panel 1 ) DRV/rtv ( Panel 2 ) morning Day 22 . From Day 8 , 3 day treatment artemether/lumefantrine . In first stage treatment Panel 2 , 4 patient allowed start Treatment B . Based ECG result first 4 patient evaluable ECG data assessment Day 11 ( 66 hour combine intake DRV/rtv artemether/lumefantrine ) , Sponsor decide whether additional patient allow start Treatment B . There washout period least 4 week Treatments A B . Half patient Panel 1 ( 8 patient ) Panel 2 ( 8 patient ) randomize sequence AB half randomize sequence BA . Randomization Panel 2 occur two step . In Step 1 , 4 patient allocate sequence BA evaluate QTc prolongation . Based outcome ECG result , Sponsor decide whether remainder patient randomized Step 2 , i.e . 4 patient BA 8 patient AB ( 1:2 randomization ) . Serial pharmacokinetic assessment determine Panels 1 2 Treatments A B artemether metabolite dihydroartemisinin ( DHA ) first intake artemether/lumefantrine 8 hour last intake artemether/lumefantrine 72 hour ( 3 day ) , lumefantrine last intake artemether/lumefantrine 264 hour ( 11 day ) . Serial pharmacokinetic assessment determine ETR ( Panel 1 ) DRV rtv ( Panel 2 ) 12-hour dose interval Day 8 ( morning intake ) Day 11 ( last dose artemether/lumefantrine ) Treatment B . All ETR , DRV/rtv artemether/lumefantrine treatment administer fed condition take within 10 minute completion meal . Safety tolerability evaluation record ongoing basis .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>childbearing potential male , use highly effective method birth control . Able comply protocol requirement . A BMI ( weight kg divide square height meter ) 18.5 30.0 kg/m2 , extremes include . healthy basis medical evaluation Nonsmoking least 3 month prior selection . previously demonstrate clinically significant allergy , hypersensitivity intolerance investigational medication excipients Use concomitant medication , include overthecounter product dietary supplement . Having participate 1 study ( single multiple dose ) ETR ( TMC125 ) , DRV ( TMC114 ) , dapivirine ( TMC120 ) and/or rilpivirine ( TMC278 , formerly know R278474 ) , develop rash , erythema urticaria participate study aforementioned compound . A positive pregnancy test breast feed screen Day 1 . Any condition , opinion investigator , would compromise study wellbeing patient prevent patient meeting perform study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>pharmacokinetic interaction</keyword>
	<keyword>healthy HIV-negative person</keyword>
</DOC>